+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 16 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effects of camoteskimab in adults aged 18 to 65 with moderate-to-severe atopic dermatitis. This phase 2b, multicenter, randomized, double-blind, placebo-controlled study aims to assess the efficacy and safety of camoteskimab compared to placebo. Participants include those who are treatment-naive or have had an inadequate response to previous biologic therapies. The study has two parts Part 1 is a 24-week placebo-controlled period where participants are randomly assigned to one of three camoteskimab dose levels or placebo, all administered by subcutaneous injection. In Part 2, an extension period, all participants receive camoteskimab. This design allows comparison of different dose levels and monitoring of long-term treatment effects. Participants will be assessed regularly throughout the study with measures including the Eczema Area and Severity Index EASI, Investigator Global Assessment IGA, and peak pruritus numerical rating scale PP-NRS. Safety and efficacy will be monitored through these assessments over 24 weeks and beyond. The study includes signing informed consent and adherence tracking, with the primary outcome focused on percentage change in EASI score from baseline to Week 24.

Age: 18Years - 65YearsAll GendersPhase 2
85 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of the study drug Seltorexant compared with a placebo in adults and elderly participants with major depressive disorder MDD, a common mood disorder marked by persistent sadness and loss of interest. This Phase 3 study includes a double-blind treatment phase to measure improvement in depressive symptoms specifically in participants with moderate-to-severe insomnia symptoms. The study also aims to assess long-term safety and tolerability of Seltorexant in an open-label treatment phase. During the double-blind phase, participants will take either a Seltorexant tablet or a matching placebo once daily for 42 days. Those who qualify for the open-label phase will continue taking Seltorexant daily for up to 6 months. The study compares the two groups to understand how well Seltorexant works alone in treating MDD. Participants will undergo clinical assessments including depression rating scales, sleep disturbance questionnaires, and safety evaluations such as vital signs, laboratory tests, electrocardiograms, and suicidality ratings. Researchers will also monitor withdrawal symptoms and sexual functioning during the open-label phase. The total participation duration may extend over several months to evaluate both efficacy and long-term safety outcomes.

Age: 18Years - 74YearsAll GendersPhase 3
53 locations
E

Actively Recruiting

Bipolar disorder is a serious and chronic mood condition affecting both adults and pediatric populations in the United States. This research aims to evaluate the safety and effectiveness of Icalcaprant in treating adults diagnosed with bipolar I or II disorder, focusing on depressive episodes. The study is a phase 2, randomized, placebo-controlled trial enrolling about 195 adults across approximately 35 sites. Participants will be randomly assigned to one of three groups two different doses of oral Icalcaprant or a matching placebo. They will take the assigned oral capsules once daily for six weeks. After the treatment period, there will be a four-week safety follow-up to monitor participants health. During the study, participants will attend regular visits at hospitals or clinics for medical assessments, blood tests, side effect monitoring, and questionnaires. The main outcomes measured include changes in depression severity using the Montgomery-sberg Depression Rating Scale and monitoring adverse events throughout the treatment and follow-up periods. This study is sponsored by AbbVie and aims to better understand treatment options for bipolar depression.

Age: 18Years - 65YearsAll GendersPhase 2
33 locations
E

Actively Recruiting

This trial is focused on adults with tardive dyskinesia TD who continue to have symptoms while taking or after stopping a vesicular monoamine transporter 2 VMAT2 inhibitor. The study evaluates the effects of valbenazine on both clinician- and patient-reported outcomes related to TD. It involves participants diagnosed with schizophrenia, schizoaffective disorder, bipolar disorder, or major depressive disorder, all of whom have experienced neuroleptic-induced TD for at least three months. Participants will receive valbenazine capsules once daily for 24 weeks. The study does not include a comparison group as it is a single-group open-label design, meaning all participants receive the same treatment. The main goal is to measure changes in abnormal involuntary movements and other symptoms during this period. Throughout the trial, participants will be assessed at the start and at week 24 using several scales, including the Abnormal Involuntary Movement Scale AIMS, Clinical Global Impression of Severity for TD, the Tardive Dyskinesia Impact Scale TDIS, and the EuroQol-Visual Analogue Scale EQ-VAS. These measures will help evaluate the severity and impact of TD symptoms. The trial is expected to last until June 2028, with ongoing monitoring of participants during treatment.

Age: 18Years +All GendersPhase 4
19 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and tolerability of ponsegromab combined with systemic chemotherapy compared to chemotherapy plus placebo for adults with metastatic pancreatic ductal adenocarcinoma mPDAC who have cachexia, a condition causing significant weight loss and fatigue. This Phase 2b3, randomized, double-blind study involves adult participants who have completed initial chemotherapy cycles and aims to improve treatment outcomes for this challenging condition. Participants will receive either one of two doses of ponsegromab or a placebo alongside first-line chemotherapy regimens consisting of nab-paclitaxel plus gemcitabine or FOLFIRINOX. The study intervention is given as a subcutaneous injection every four weeks. After an initial Phase 2b period where doses are evaluated, the study continues into Phase 3 with the selected ponsegromab dose or placebo. Participants may also join an optional open-label extension to receive ponsegromab for up to 12 months after the double-blind phase ends. During the study, participants will have tumor assessments approximately every 6 to 8 weeks by independent radiologists. The research team will monitor body weight changes, physical activity, quality of life measures, safety events, and survival outcomes over the course of the trial, which may last up to several years. Caregiver quality of life is also evaluated in an optional sub-study. Participants health and treatment effects will be closely followed until the studys completion in 2029.

Age: 18Years +All GendersPhase 2Phase 3
230 locations
E

Actively Recruiting

Researchers are evaluating how well tilrekimig works, its safety, and effects on the body in adults and adolescents aged 12 years and older with moderate to severe atopic dermatitis, a skin condition causing dryness, itching, and redness. The study includes participants who have had atopic dermatitis for at least one year and have not responded well to topical medicines. The trial is a Phase 3 randomized, double-blind study comparing tilrekimig, dupilumab, and placebo. Participants will receive subcutaneous injections during a 24-week initial treatment period, randomized in a 221 ratio to tilrekimig, dupilumab, or placebo. This is followed by a 28-week maintenance period where study drugs continue until the last dose at week 48. Some participants may join a long-term extension study at week 52 to further evaluate treatment effects and safety, while others will enter a 12-week safety follow-up period after their last dose. During the trial, participants will have regular visits for assessments including skin evaluations using the Eczema Area and Severity Index EASI and Investigator Global Assessment scales. Other measures include patient-reported skin itch severity and quality of life questionnaires. Safety is monitored through adverse event tracking, vital signs, and laboratory tests, with follow-up continuing for at least 16 weeks after the last dose. The total study participation lasts up to 64 weeks, including treatment and follow-up periods.

Age: 12Years +All GendersPhase 3
32 locations
O

Actively Recruiting

Researchers are observing adults diagnosed with schizophrenia in the United States who have started treatment with xanomeline and trospium chloride KarXT. The study aims to describe real-world treatment patterns, effectiveness, and adverse events related to KarXT use in routine clinical care. Participants are those who have initiated KarXT treatment within 16 weeks with plans to discontinue prior antipsychotic treatments or are on stable antipsychotic regimens planning to switch to KarXT. The study follows these participants for up to 20 weeks to record treatment titration, switches, and continuation patterns. Concomitant psychiatric medications may continue at stable doses during the study. During the study, researchers collect data on adverse events, weight changes, clinical global improvement scores, schizophrenia-related relapses, treatment discontinuation reasons, and use of antiemetic treatments for gastrointestinal symptoms. Baseline information includes demographics, family history, diagnosis duration, and previous treatments. This observational study supports understanding KarXT treatment in real-world settings up to 20 weeks after initiation.

Age: 18Years +All Genders
68 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness of NBI-1065890 compared to a placebo for treating tardive dyskinesia TD in adults. This Phase 2 study focuses on adults aged 18 to 75 with a confirmed diagnosis of TD caused by neuroleptic medication and other related psychiatric conditions such as schizophrenia, schizoaffective disorder, bipolar disorder, or major depressive disorder. The study aims to assess the treatments impact on abnormal involuntary movements and overall improvement. Participants will be randomly assigned to receive either NBI-1065890 or a matching placebo, both taken orally. The study uses a parallel design with quadruple masking to compare the effects over an 8-week period. The main measurement is the change in the Abnormal Involuntary Movement Scale AIMS total score from baseline to week 8, along with secondary assessments of clinical global improvement. During the study, participants will undergo blinded video assessments of their movements, and their responses will be evaluated by expert raters. Researchers will monitor the severity of dyskinesia, psychiatric symptoms, and any side effects. The study includes regular visits over the 8-week treatment period, with safety and tolerability closely observed. Total participation lasts at least 8 weeks, concluding with the final evaluation of movement improvement.

Age: 18Years - 75YearsAll GendersPhase 2
18 locations
L

Actively Recruiting

Researchers are studying the long-term safety and tolerability of the drug NBI-1065845 when used alongside other treatments for adults with Major Depressive Disorder MDD. This Phase 3 trial focuses on participants who have moderate to severe recurrent MDD or persistent depressive disorder, particularly those who have not responded well to oral antidepressants in their current depressive episode. Participants will take NBI-1065845 tablets orally once a day as an additional treatment. The study is open-label and single group, meaning all participants receive the same treatment. The trial will observe participants over the course of one year while they take the medication. During the study, participants will undergo assessments to monitor any treatment-emergent adverse events from the start through week 52. Researchers will evaluate how well participants tolerate the medication and ensure their safety throughout the treatment period. The total participation duration corresponds to the one-year treatment and monitoring phase.

Age: 18Years +All GendersPhase 3
120 locations
S

Actively Recruiting

Researchers are evaluating the effectiveness of NBI-1065845 compared with a placebo as an additional treatment to improve symptoms in adults with major depressive disorder MDD. The study focuses on participants who have recurrent moderate to severe MDD or persistent depressive disorder and who have not responded adequately to oral antidepressants in their current episode. This Phase 3 trial is designed to assess both the efficacy and safety of this investigational drug. Participants will be randomly assigned to receive either NBI-1065845 or a matching placebo, both administered orally once a day. The study is double-blind, meaning neither participants nor researchers know which treatment is given. Treatment duration lasts 56 days, during which participants continue their current oral antidepressant medication at the same dose. The study uses a parallel design with two groups receiving either the drug or placebo. During the trial, participants will be assessed at baseline and at Day 56 using several scales to measure changes in depression severity and disability. These include the Montgomery-5sberg Depression Rating Scale MADRS, the Sheehan Disability Scale SDS, and the Clinical Global Impression-Severity Scale CGI-S. Participants must comply with all study procedures and restrictions, and their safety and response to treatment will be closely monitored throughout the study period, which ends in July 2027.

Age: 18Years +All GendersPhase 3
39 locations

1-10 of 16

1